Creabilis: Eliot Forster. Innovation in dermatology




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Creabilis: Eliot Forster. Innovation in dermatology
Released on: June 27, 2013. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this episode of PharmaTelevision News Review, filmed at BioTrinity 2013, Newbury UK, Fintan Walton speaks to Eliot Forster of Creabilis.
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, filmed at BioTrinity 2013, Newbury UK, Fintan Walton speaks to Eliot Forster of Creabilis.
In this episode of PharmaTelevision News Review, filmed at BioTrinity 2013, Newbury UK, Fintan Walton speaks to Eliot Forster of Creabilis.
Eliot Forster
Creabilis
Creabilis
Creabilis is a late clinical stage European biotechnology company with corporate and R&D functions located in the UK and Italy. Creabilis’ primary focus is in chronic pruritus, a debilitating symptom of many dermatological diseases with a negative impact on quality of life. Chronic pruritus is an area of significant unmet need, with no medicine currently approved for its treatment. Creabilis has delivered positive Phase 2b results for CT327 in the treatment of pruritus in psoriasis patients. CT327 is a novel, first-in-class, topically delivered TrkA kinase inhibitor. CT327 was developed using Creabilis’ proprietary Low Systemic Exposure (LSE) 'topical-by-design' technology. LSE creates molecules optimized for topical applications. Planning for Phase 3 with CT327 is underway, with a clear route to market and an estimated $800m+ in peak annual sales. Creabilis’ pipeline also includes CT340, a potent narrow spectrum kinase inhibitor in development for the topical treatment of neuropathic pain, an area of significant unmet medical need. Like CT327, CT340 was developed using the Company’s Low Systemic Exposure (LSE) technology. CT340 is IND-ready and first-in-human studies will commence in 2013. Creabilis is backed by highly respected life science investors Sofinnova Partners, Neomed and AbbVie Biotech Ventures Inc., and is led by an experienced Management team, with over 100 years of combined R&D experience in pharma and biotech, and over 20 drug approvals.